Established and designated by the National Cancer Institute (NCI) as one of the eight original comprehensive cancer centers in 1973, today the Duke Cancer Institute is one of only 41 cancer centers which hold that distinction. Continually ranked among the leading cancer programs in the nation by U.S. News & World Report, the DCI is a single entity that integrates and aligns patient care and research with the goals of improving patient outcomes, decreasing the burden of cancer and accelerating scientific progress. More than 300 DCI clinicians and researchers are dedicated to a broad spectrum of cancer research and the translation of that research into the latest in patient care. The DCI comprises nine NCI-designated programs, representing areas of specialized expertise and focus on basic, translational, clinical, and population research.
Duke University Hospital and the Duke Cancer Institute have approximately 9,000 inpatient and more than 300,000 outpatient encounters annually for patients with cancer as a primary or secondary diagnosis, including approximately 600 patients a week who receive chemotherapy. Patients treated at the Duke Cancer Institute represent virtually every county in North Carolina and every state in the nation. The new Duke Cancer Center facility for ambulatory care opened in February 2012 and is a cornerstone of the DCI.
The Duke Cancer Institute offers care for patients with all – even the most rare – forms of cancer and is nationally recognized for its brain tumor and blood and marrow transplantation programs. Patients at the DCI receive a complete spectrum of care, from prevention and diagnosis, through treatment and survivorship. Their care is managed by multidisciplinary teams of specialists providing individualized and coordinated care. Patients benefit from the most advanced treatments, many of them available through the DCI's large portfolio of clinical trials. Support services and survivorship resources are also available to patients and their families throughout their experience with cancer.